Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

Grants

Funding Acknowledgements

This retrospective analysis was designed by external investigators in collaboration with the sponsor (Merck). The sponsor performed the statistical analysis. The authors were actively involved in the collection, analysis, or interpretation of the data, revising the manuscript for intellectual content, and approval of the final manuscript. All authors had full access to the data and had final responsibility for the decision to submit for publication. EAJ assumes full responsibility for the overall content and integrity of the manuscript.The study was funded by Merck, Sharp, & Dohme, Whitehouse Station.All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that EAJ has received advisory board fees from Merck, and funding through his institution to conduct epidemiological HPV studies for GlaxoSmithKline. He has received lecture fees from Merck, Sanofi Pasteur MSD, and GlaxoSmithKline. SMG has received advisory board fees and grant support from Commonwealth Serum Laboratories and GlaxoSmithKline, and lecture fees from Merck and Sanofi Pasteur MSD. She has received funding through her institutions to conduct HPV vaccine studies for GlaxoSmithKline. DGF has received consultancy fees and funding through his institution to conduct HPV vaccine studies for GlaxoSmithKline, and lecture fees, advisory board fees, and consulting from Merck. GP has received lecture fees from Merck and Sanofi Pasteur MSD and is now an employee of Merck. KAA has received consultancy and advisory board fees from Merck, and has received funding through his institution to conduct HPV vaccine studies for GlaxoSmithKline, Roche, and the National Institute for Allergy and Infectious Diseases, and for non-vaccine clinical trials for Gen-Probe. WKH has received advisory board and lecture fees from Merck. He has received advisory board fee from GlaxoSmithKline. In addition, EAJ, SMG, DGF JP, KA, and WKH have received funding through their institutions to conduct HPV vaccine studies for Merck. HLS, MKJ, GP, and RMH and are employees of Merck and potentially own stock or stock options in the company.